| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Naveed Sattar | Q37378984 |
| Frances Mair | Q38589247 | ||
| Barbara Nicholl | Q42785274 | ||
| Sarah Barry | Q56929804 | ||
| P2093 | author name string | Gary McLean | |
| Jonathan Cavanagh | |||
| Bhautesh D Jani | |||
| P2860 | cites work | DSM-5 | Q3064664 |
| Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 | ||
| Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile | Q21245293 | ||
| Antidepressant drug effects and depression severity: a patient-level meta-analysis | Q24598580 | ||
| Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine | Q24607720 | ||
| The genetics of major depression | Q26830784 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Stress and the individual. Mechanisms leading to disease | Q28262768 | ||
| Stress, adaptation, and disease. Allostasis and allostatic load | Q28273842 | ||
| Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis | Q28292593 | ||
| Translating clinical research into clinical practice: impact of using prediction rules to make decisions | Q28295968 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Predicting inpatient violence using an extended version of the Brøset-Violence-Checklist: instrument development and clinical application | Q33241061 | ||
| A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers | Q33587452 | ||
| Differences between human plasma and serum metabolite profiles | Q33961437 | ||
| Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study | Q34123494 | ||
| Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned | Q34147518 | ||
| Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). | Q34206044 | ||
| Biomarkers to predict antidepressant response | Q34247513 | ||
| Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. | Q34386877 | ||
| Definitions and factors associated with subthreshold depressive conditions: a systematic review | Q34461494 | ||
| Preventing relapse and recurrence of depression: a brief review of therapeutic options. | Q34587416 | ||
| The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression | Q34789260 | ||
| Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. | Q35040553 | ||
| The heterogeneity of "major depression" | Q35286025 | ||
| Functional biomarkers of depression: diagnosis, treatment, and pathophysiology | Q35356872 | ||
| Is impaired neurogenesis relevant to the affective symptoms of depression? | Q35844562 | ||
| Glucocorticoids, cytokines and brain abnormalities in depression | Q36442019 | ||
| Identification and validation of urinary metabolite biomarkers for major depressive disorder | Q36508139 | ||
| Psychological treatments of subthreshold depression: a meta-analytic review. | Q36820053 | ||
| Prevalence and management of treatment-resistant depression. | Q36886267 | ||
| Depression, antidepressants, and peripheral blood components. | Q37087926 | ||
| No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis | Q37116846 | ||
| Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results | Q37119504 | ||
| Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. | Q37310786 | ||
| Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap | Q37385194 | ||
| Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response | Q37483986 | ||
| Major depressive disorder treatment guidelines in America and Europe | Q37725179 | ||
| Can effects of antidepressants in patients with mild depression be considered as clinically significant? | Q37884961 | ||
| Novel biomarkers in major depression | Q38060084 | ||
| A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers | Q38150622 | ||
| HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. | Q38475587 | ||
| How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression | Q39584554 | ||
| Use and misuse of the receiver operating characteristic curve in risk prediction | Q40241086 | ||
| Prognosis of late life depression: a three-year cohort study of outcome and potential predictors | Q40368213 | ||
| C-reactive protein, depressed mood, and the prediction of coronary heart disease in initially healthy men: results from the MONICA-KORA Augsburg Cohort Study 1984-1998. | Q40393807 | ||
| Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database | Q40665713 | ||
| The DST as a predictor of outcome in depression: a meta-analysis | Q40768542 | ||
| Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder | Q42950518 | ||
| Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research | Q43789984 | ||
| Allostatic load associations to acute, 3-year and 6-year prospective depressive symptoms in healthy older adults | Q43864203 | ||
| Clinical diagnosis of depression in primary care: a meta-analysis | Q44323103 | ||
| Influence of anticoagulants on the measurement of S100B protein in blood | Q44668299 | ||
| Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment. | Q45276681 | ||
| Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1? and soluble interleukin-2 receptor production | Q46080463 | ||
| HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients | Q46215404 | ||
| Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons | Q47192384 | ||
| S100B and response to treatment in major depression: a pilot study | Q48240145 | ||
| An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline | Q48255615 | ||
| Total and free tryptophan concentration in the plasma of depressive patients. | Q48643863 | ||
| Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. | Q48658510 | ||
| Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. | Q48715974 | ||
| Plasma metabonomics as a novel diagnostic approach for major depressive disorder. | Q48760949 | ||
| Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. | Q48826806 | ||
| Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-V. | Q48859763 | ||
| Depression, chronic diseases, and decrements in health: results from the World Health Surveys. | Q51906370 | ||
| Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. | Q51919473 | ||
| Excess mortality in depression: a meta-analysis of community studies. | Q51952074 | ||
| Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated? | Q51966732 | ||
| Plasma norepinephrine and prediction of outcome in major depressive disorder. | Q51980179 | ||
| Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression | Q56767079 | ||
| Relationship Between Blood Serotonergic Variables, Melancholic Traits, and Response to Antidepressant Treatments | Q60641047 | ||
| A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility | Q71465909 | ||
| Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode | Q71500883 | ||
| Cytokine production and treatment response in major depressive disorder | Q73505932 | ||
| The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline | Q73851879 | ||
| Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? | Q77396603 | ||
| Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability | Q81338893 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 18 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Frontiers in Human Neuroscience | Q15727054 |
| P1476 | title | Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers | |
| P478 | volume | 9 |
Search more.